One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Cullinan Therapeutics secured global rights, excluding Greater China, to velinotamig from Genrix Bio, expanding its autoimmune pipeline with a second T cell engager.
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent dosing benefits.
Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims to advance Merck's pipeline for treating B-cell malignancies and autoimmune diseases. The deal, valued at up to $1.3 billion, is expected to close in Q3 2024.
